PuSH - Publikationsserver des Helmholtz Zentrums München: RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Van Eeckhoutte, H.P.* ; Donovan, C.* ; Kim, R.Y.* ; Conlon, T.M. ; Ansari, M. ; Khan, H.* ; Jayaraman, R.* ; Hansbro, N.G.* ; Dondelinger, Y.* ; Delanghe, T.* ; Beal, A.M.* ; Geddes, B.* ; Bertin, J.* ; Berghe, T.V.* ; De Volder, J.* ; Maes, T.* ; Vandenabeele, P.* ; Vanaudenaerde, B.M.* ; Deforce, D.* ; Škevin, S.* ; Van Nieuwerburgh, F.* ; Verhamme, F.M.* ; Joos, G.F.* ; Idrees, S.* ; Schiller, H. B. ; Yildirim, A.Ö. ; Faiz, A.* ; Bertrand, M.J.M.* ; Brusselle, G.G.* ; Hansbro, P.M.* ; Bracke, K.R.*

RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD.

Eur. Respir. J. 61:2201506 (2022)

Postprint

DOI

PMC

	Open Access Green

Abstract
Metriken
Zusatzinfos

RATIONALE: Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of regulated cell death (including apoptosis and necroptosis) and inflammation, both drivers of chronic obstructive pulmonary disease (COPD) pathogenesis. OBJECTIVE: We aimed to define the contribution of RIPK1 kinase-dependent cell death and inflammation in the pathogenesis of COPD. METHODS: We assessed RIPK1 expression in single-cell RNA-sequencing data from human and mouse lungs and validated RIPK1 levels in lung tissue of COPD patients via immunohistochemistry. Next, we assessed the consequences of genetic and pharmacological inhibition of RIPK1 kinase activity in experimental COPD, using Ripk1^S25D ^/S25D kinase deficient mice and the RIPK1 kinase inhibitor GSK'547. MEASUREMENTS AND MAIN RESULTS: RIPK1 expression increased in alveolar type I (AT1), AT2, ciliated and neuroendocrine cells in human COPD. RIPK1 protein levels were significantly increased in airway epithelium of COPD patients, compared to never smokers and smokers without airflow limitation. In mice, exposure to cigarette smoke (CS) increased Ripk1 expression similarly in AT2 cells, and further in alveolar macrophages and T cells. Genetic and/or pharmacological inhibition of RIPK1 kinase activity significantly attenuated airway inflammation upon acute and subacute CS-exposure, as well as airway remodeling, emphysema and apoptotic and necroptotic cell death upon chronic CS-exposure. Similarly, pharmacological RIPK1 kinase inhibition significantly attenuated elastase-induced emphysema and lung function decline. Finally, RNA-sequencing on lung tissue of CS-exposed mice revealed downregulation of cell death and inflammatory pathways upon pharmacological RIPK1 kinase inhibition. CONCLUSIONS: RIPK1 kinase inhibition is protective in experimental models of COPD and may represent a novel promising therapeutic approach.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

33.795

0.000